Medications

Ozempic vs Mounjaro: How the Two Diabetes Shots Compare

Ozempic and Mounjaro are both once-weekly injections for type 2 diabetes, but they are different molecules with different dosing ladders, different extra indications and different device options.

Last verified September 14, 2026·10 sources cited·Ozempic Mounjaro

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Ozempic and Mounjaro sit next to each other in nearly every conversation about type 2 diabetes, and for good reason. Both are once-weekly injections. Both lower A1C substantially. Both cause weight loss as a side effect. And both carry the same boxed warning.

They are not the same medicine. Here is where they actually differ.

What is in each one?

Ozempic contains semaglutide, a GLP-1 receptor agonist. It mimics one gut hormone [1].

Mounjaro contains tirzepatide, which activates two receptors: GIP and GLP-1 [2]. That dual action is why it is often described as a “twincretin” rather than a straight GLP-1.

Because the molecules are different, the milligram numbers mean nothing to each other. Mounjaro 5 mg is not “twice as strong” as Ozempic 2.5 mg. There is no conversion table.

What is each one approved to treat?

This is the most useful difference, and it changed in 2026.

Ozempic injection is approved for [1]:

Improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise
Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (approved January 2020)
Reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (approved January 28, 2025)

That kidney indication, based on the FLOW trial, is unique in the GLP-1 class [3].

Mounjaro is approved for [2]:

Improving blood sugar control in adults and pediatric patients aged 10 and older with type 2 diabetes, alongside diet and exercise
Reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events (approved August 28, 2026)

Two things stand out. Mounjaro reaches children as young as 10, following the SURPASS-PEDS trial; Ozempic is adults only [6][7]. And Mounjaro only picked up its cardiovascular indication in August 2026, more than six years after Ozempic did [5].

Neither is approved for weight loss. Both manufacturers sell a separate obesity product using the same molecule: Wegovy for semaglutide, Zepbound for tirzepatide.

What does the dosing look like?

Ozempic [1]:

Step	Dose
Weeks 1-4	0.25 mg once weekly
From week 5	0.5 mg once weekly
After at least 4 weeks on 0.5 mg, if needed	1 mg once weekly
After at least 4 weeks on 1 mg, if needed	2 mg once weekly

The label notes that for the kidney indication the dose should be increased to 1 mg after at least four weeks on 0.5 mg. If a dose is missed, the label says to take it within five days of the missed dose.

Mounjaro [2]:

Step	Dose
Start	2.5 mg once weekly
Each escalation, after at least 4 weeks	+2.5 mg
Maximum in adults	15 mg once weekly
Maximum in children 10 and older	10 mg once weekly

Mounjaro’s ladder has six rungs: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Ozempic’s has four. On missed doses the two labels differ: Ozempic allows catching up within five days, while Mounjaro’s label says to take a missed dose within four days (96 hours) and otherwise skip it [1][2].

Both are injected under the skin of the abdomen, thigh or upper arm, once a week, at any time of day, with or without meals. Mounjaro’s label adds that an upper-arm injection should be given by another person, and that injection sites should be rotated with each dose [2].

What does the head-to-head trial show?

SURPASS-2 compared tirzepatide directly against semaglutide 1 mg in adults with type 2 diabetes. Results published in the New England Journal of Medicine in June 2021 showed tirzepatide achieving superior A1C and body weight reductions across all three doses tested [4].

Two caveats matter when reading that. The comparator was semaglutide 1 mg, not the 2 mg dose that FDA approved in March 2022. And the trial measured blood sugar and weight, not long-term outcomes like heart attacks or kidney failure.

For those outcomes, each drug has its own trial: SELECT and FLOW for semaglutide, SURPASS-CVOT for tirzepatide. No trial has compared them head to head on cardiovascular events.

Which devices do they come in?

This is where Mounjaro has more options.

Ozempic comes as multi-dose single-patient-use pens in three configurations [1]:

2 mg/3 mL pen: four 0.25 mg doses then two 0.5 mg doses, or four 0.5 mg doses (6 needles in the carton)
4 mg/3 mL pen: four 1 mg doses (4 needles)
8 mg/3 mL pen: four 2 mg doses (4 needles)

The current label also lists single-dose prefilled syringes at 0.25, 0.5 and 1 mg, four to a carton.

Mounjaro comes four ways [2]:

Single-dose prefilled pen, four per carton
Single-dose vial, one per carton
Multi-dose vial holding four doses
Single-patient-use KwikPen holding four weekly doses

Vials need a separate needle and syringe; KwikPens need separate pen needles. Ozempic pens ship with their needles included.

How do you store them?

The storage rules are genuinely different, and getting them wrong wastes medicine.

Ozempic pens [1]: refrigerate at 2 to 8 degrees Celsius (36 to 46 Fahrenheit) before first use. After first use, the pen can be kept for 56 days at room temperature, 15 to 30 degrees Celsius (59 to 86 Fahrenheit), or back in the refrigerator. Do not freeze. Keep the cap on and store the pen without a needle attached.

Ozempic prefilled syringes [1]: refrigerate 2 to 8 degrees Celsius; if needed, 8 to 30 degrees Celsius for up to 28 days. Discard after use.

Mounjaro single-dose pens and vials [2]: refrigerate 2 to 8 degrees Celsius. Each one can be kept unrefrigerated at no more than 30 degrees Celsius for a total of 21 days, then must be discarded. Once it has been at room temperature it should not go back in the refrigerator.

Mounjaro multi-dose vials and KwikPens [2]: refrigerate unopened until the expiration date, or discard after 30 days if kept unopened at room temperature. Once in use, discard after 30 days at room temperature, 30 days after first use, or four weekly doses, whichever comes first.

Both labels say the same thing about freezing: do not, and do not use the product if it has been frozen.

What do they cost?

Both sit in the same rough price band at list, and both have programs that bring cash prices far below it.

Through Novo Nordisk’s NovoCare Pharmacy and savings offers in 2026, self-pay Ozempic is $199 a month for the first two fills of 0.25 or 0.5 mg for patients new to the program, then $349 a month for 0.25, 0.5 or 1 mg and $499 a month for 2 mg (verified 2026-09-14) [10]. Commercially insured patients may pay as little as $25 a month, subject to a $100 monthly savings cap — a copay tier, not a self-pay price.

Novo Nordisk also announced on February 24, 2026 that the list price of Ozempic injection 0.5, 1 and 2 mg will fall to $675 a month effective January 1, 2027, about a 35% cut. The company said self-pay prices are unaffected.

For both drugs, the November 2025 federal pricing agreement set a $245 per month price for injectable Ozempic, Wegovy, Mounjaro and Zepbound in Medicare and state Medicaid programs, with a $50 monthly copay for Medicare beneficiaries [9].

If you have insurance, coverage rules usually matter more than list price. Diabetes indications are far more widely covered than obesity ones, which is part of why some people end up on Ozempic or Mounjaro rather than Wegovy or Zepbound.

What are the side effects?

The most common reactions look similar because both drugs slow the stomach and act on appetite pathways.

Ozempic’s label lists nausea, vomiting, diarrhea, abdominal pain and constipation among reactions occurring in 5% or more of patients [1]. Mounjaro’s adds decreased appetite and dyspepsia to a similar list [2].

Both carry the same boxed warning: in rodents these drugs caused thyroid C-cell tumors, and it is unknown whether they do in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1][2].

Both labels also warn about acute pancreatitis, low blood sugar when combined with insulin or sulfonylureas, acute kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, gallbladder disease, diabetic retinopathy complications, and the risk of food or liquid entering the lungs during anesthesia or deep sedation.

In October 2025 a severe gastrointestinal adverse reactions warning was added to the semaglutide labels [1].

So which one should you be on?

That is a medical decision, and the useful questions to bring to an appointment are practical ones:

Do you have chronic kidney disease alongside type 2 diabetes? Only Ozempic carries that indication.
Is the patient a child aged 10 to 17? Only Mounjaro is approved there.
How much A1C reduction do you need, and how did you tolerate escalation on anything you have tried before?
What does your plan actually cover, and at what copay?
Do you prefer a pen with needles included, or would a vial or multi-dose KwikPen suit you better?

One rule applies to both: the labels say not to use tirzepatide alongside another tirzepatide product or any GLP-1 receptor agonist, and the same restriction applies to semaglutide products [1][2]. You do not stack these.

Sources

This article is general information, not medical advice. Talk to a healthcare provider about which medicine, if any, is appropriate for you.

Questions people ask

Is Mounjaro better than Ozempic?

In SURPASS-2, a head-to-head trial in adults with type 2 diabetes, all three tirzepatide doses produced greater A1C and body weight reductions than semaglutide 1 mg. But 'better' depends on what you need. Ozempic is the only GLP-1 with an FDA-approved indication for slowing chronic kidney disease in type 2 diabetes, and both now carry a cardiovascular indication. This is a conversation for your healthcare provider.

Are Ozempic and Mounjaro the same type of drug?

Not quite. Ozempic contains semaglutide, a pure GLP-1 receptor agonist. Mounjaro contains tirzepatide, which activates both the GIP and the GLP-1 receptor. People group them together, but they are different molecules and the doses are not comparable.

Can you use Ozempic or Mounjaro for weight loss?

Neither is FDA-approved for weight loss. Both manufacturers sell a separate product for that: Wegovy is the semaglutide version and Zepbound is the tirzepatide version. Some prescribers use the diabetes brands off label, but insurance rarely covers that.

Can I switch from Ozempic to Mounjaro?

There is no official milligram-for-milligram conversion between semaglutide and tirzepatide, because they are different molecules. If a switch is made, the Mounjaro label directs starting at 2.5 mg once weekly and stepping up in 2.5 mg increments after at least four weeks. Only a prescriber can decide whether a switch is appropriate.

Which one is approved for kidney disease?

Only Ozempic. In January 2025 FDA approved Ozempic injection to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. Mounjaro does not carry that indication.

Can children take either of these?

Mounjaro is approved for pediatric patients aged 10 and older with type 2 diabetes, with a maximum dose of 10 mg once weekly. Ozempic is approved for adults only.

Do they have different side effects?

The common side effects overlap heavily: nausea, diarrhea, vomiting, constipation and stomach pain lead the list for both. Both carry the same boxed warning about thyroid C-cell tumors in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Mounjaro's label also lists decreased appetite among its most common reactions.

How long can each pen sit out of the refrigerator?

The Ozempic multi-dose pen may be kept at 15 to 30 degrees Celsius for up to 56 days after first use. Mounjaro single-dose pens and vials may be kept unrefrigerated at no more than 30 degrees Celsius for a total of 21 days, then must be discarded. Mounjaro multi-dose vials and the KwikPen get 30 days rather than 21, counted from first use or from the start of room-temperature storage, or four weekly doses, whichever comes first.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.